Nausicaa Ventures is a venture capital investment firm specializing in early-stage, later-stage, series C and D round, growth-stage and seed-stage capital investments. The firm prefers to invest in companies based in Benelux, France, Switzerland and the United Kingdom operating in the healthcare, medical technology, information and communication technology, high-technology, manufacturing and clean technology sectors. It was founded in 2009 and is based in Louvain-la-Neuve, Belgium.
Nausicaa Ventures was created in 2009 by bringing together 35 private investors and selected institutional investors, such as the European Investment Fund or ING Bank, under the management of an experienced investment team. The target size of Nausicaa Ventures is upwards of €20 million.
Nausicaa Ventures combines the best of institutional venture capital groups and individual investors. It aims to cover the equity gap faced by most early stage companies on their path towards growth. Nausicaa Ventures has the resources, knowledge, and experience to respond to the financial and management needs of those companies, and to work side-by-side with them towards the achievement of successful exits.
Bone Therapeutics is a biotechnology company developing cell therapy treatments for orthopaedics and bone disease.
Co-Founder and General Partner
Michel Helbig de Balzac
Co-Founder and Managing Partner